Article
Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).
Cancer - 1 Oct 2018
Hata Akito, Katakami Nobuyuki, Kaji Reiko, Yokoyama Toshihide, Kaneda Toshihiko, Tamiya Motohiro, Inoue Takako, Kimura Hiromi, Yano Yukihiro, Tamura Daisuke, Morita Satoshi, Negoro Shunichi, The Hanshin Oncology Group For
Abstract excerpt
BACKGROUND: Preclinical studies suggested that the addition of bevacizumab could overcome acquired resistance (AR) to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The aim of this study was to evaluate the clinical efficacy and safety of a combination of afatinib and bevacizumab after AR. METHODS: Patients with EGFR-mutant non-small cell lung cancer after AR were enrolled during any...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.